marijuana stocks to buy

interesting - search results

If you're not happy with the results, please do another search

0 214

Totally Hemp Crazy Inc. Announces Harry Drnec Named as Advisory Director

 Totally Hemp Crazy Inc. (OTC PINK: THCZ) announced today the appointment of Harry Drnec as Advisor to the Board of Directors. Mr. Drnec brings a world of experience in new product development and product launching; experience he developed under a diverse repertoire of beverage companies. He is the former Managing Director of Red Bull UK. At Red Bull, Mr. Drnec lifted a failing brand, impacting sales from 3M cans in 1996 to 300M cans in 2006. He was also the Brand Manager that launched the largest selling beer brand in the world, Bud Light, with Anheuser Busch, later launching Budweiser and Michelob across Europe. Mr. Drnec also served as a Senior Marketer for Ernest and Julio Gallo. Over the next few months, THCZ will formulate a total marketing plan for the Company under the guidance and expertise of Mr. Drnec.

Mr. Drnec stated, “I am extremely excited about this new segment of the drink industry, and I love the direction that Rocky Mountain High is taking.”

Jerry Grisaffi, Founder of THCZ, remarked, “We are very excited to welcome Mr. Drnec to our company and look forward to capitalizing on his wealth of knowledge of the beverage industry.”

Rhino Marketing was appointed by THCZ to build and manage their global marketing platform and launch strategy. Rhino Marketing CEO, Thomas Hensey, exclaimed, “Harry has been a mentor of mine for years, and I cannot express in words just how pleased I am to now be working hand in hand with Harry on the marketing of the Rocky Mountain High brand line-up.”

Totally Hemp Crazy Inc. will be featured on a national radio show, Your Monies Worth, on Friday, May 15th at 12:00 noon Eastern Time. Tom Shuman, CEO of THCZ and Jerry Grisaffi will be interviewed by longtime radio host, Mick Bazsuly of WWNN AM Miami-Fort Lauderdale.

The interview will be aired live worldwide on: and

The webcast can be found at: and

The radio show, Your Monies Worth has been continuously aired for thirteen years and is centered on interesting growth companies with unique potential.

About Totally Hemp Crazy Inc.:

Totally Hemp Crazy manufactures Rocky Mountain High hemp beverage infused drinks – a range of wickedly delicious hemp based beverages that is 100% legal and refreshing!

Visit us at:

Visit us at:

Visit us at Investor Hangout:

Safe Harbor Act:
This release includes forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward looking statements in order to reflect events or circumstances that may arise after the date of this release.


Jerry Grisaffi
Email Contact

Investor Relations:
The Eversull Group, Inc.
Jack Eversull
Email Contact

0 312

If any person was born after 1983 they have most likely encountered a D.A.R.E representative. Typically local law enforcement will visit sixth-grade classrooms with charts, reports and commonly freighting, and more times than not erroneous, information about drugs. The effectiveness of the D.A.R.E. program which was initiated by the late ex-LAPD chief Daryl Gates, has been presented obstacles over the years and currently with a thorough investigation conducted by the National Center for Biotechnology Information has came to the result that D.A.R.E. is ineffective.

It looks like D.A.R.E. has gone full circle and is a joke… or at least can determine what a joke is.
“Marijuana candies, sold on the street as ‘Uncle Tweety’s Chewy Flipper’ and ‘Gummy Satans’ are taking the country by storm,” an interesting read on D.A.R.E.’s website recently.
When a writer for the Washington Post Wonkblog called to find out about the posting, D.A.R.E. immediately took it off their site with no comment, however, the story was kept by the Internet Archive.
And it only gets better.
“It is sad that in a country as developed as America, such third world drugs such as marijuana are allowed to exist,” the different story’s anonymous author wrote. “Children are being addicted to marijuana. I knew this day would come when a liberal president allowed a state to legally sell Marijuana Flintstone Vitamins to children.”
The fake article continued to make outright preposterous claims, which D.A.R.E. reposted every word in a panicked attempt to hold on to any articles displaying the cons of cannabis
“Marijuana. It is one of the most dangerous drugs on Earth.”
“For every one joint of marijuana, four teenagers become burdened with pregnancy.”
Violent offenses, fits of primal aggression, heart issues, low testosterone, heart conditions, COPD, are all the conclusions of using cannabis, according to the very funny satirical posting.
Back in 2012, the Obama administration terminated the “national Drug Abuse Resistance Education Day” however D.A.R.E. still obtains funding from the Justice Department, and various other government agencies, foundations and corporations.

0 566

There’s a battle being fought in Texas. Both sides are impassioned and not willing to back down any time soon. No, this battle isn’t about land or religion – it’s over the use of marijuana.  As many polls continue to show, a large majority of Texans support medical marijuana. In fact, 76% of Texans support possession and use of marijuana in some form. This comes as no surprise considering the amount of Texan police resources that have historically been allocated to fighting cannabis crime.  It appears that both native and transplant Texans are ready for a change.

Texas is the second largest state by land mass and second only to California in population. The potential medical and recreational marijuana tax revenue alone is projected to be over $166,303,963 for Texas.

Texas House Bill 507 was recently revived & passed in the House. It will now move on the committee that controls the floor calendar. It is expected to be stopped in it tracks until next session.

No matter what happen next for Texas, this will continue to be an interesting state to watch.

0 227

Totally Hemp Crazy Inc. to Be Featured on a National Broadcast Radio Show

Totally Hemp Crazy Inc. (OTC PINK: THCZ) announced today it will be featured on the national radio show “Your Monies Worth” on Friday, May 15th at 12 noon. Tom Shuman, CEO of THCZ, and Jerry Grisaffi, Founder of THCZ, will be interviewed by longtime radio host Mick Bazsuly of WWNN AM Miami-Fort Lauderdale.

The interview will be aired live worldwide on:

Webcast can be found at: and

The radio show “Your Monies Worth” has been continuously aired for thirteen years and is centered on interesting growth companies with unique potential.

Mick Bazsuly commented, “Hemp is the hottest industry today with many States now following the leads of the nation’s capital, Colorado, Washington State and Oregon as to immediate legalization. Its medical values are well known and the production being sold has all those benefits without the dangers of the caffeine overload as most energy drinks have today.”

Bazsuly continued, “This week’s radio show will also feature Cleartronics, another company of interest. We are always looking for companies we believe are heading north with rapid growth. These two solid growth companies represent leaders in their respective industries.”

Jerry Grisaffi, Founder of Totally Hemp Crazy, stated, “The Rocky Mountain High retail product launch is underway and based on initial sales and consumer reactions, we are convinced we have something special. In just a few short months, production has exceeded 1,000,000 units and we have another larger production run scheduled for June. We are confident our rapid growth will lead to a nationwide hemp infused drink sensation. Based on the current feedback from other parties, we are not alone in that belief.”

About Totally Hemp Crazy Inc.: 

Totally Hemp Crazy manufactures Rocky Mountain High hemp beverage drinks — a range of wickedly delicious hemp based beverages that is 100% legal and refreshing!

Visit us at:

Visit us at:

Visit us at Investor Hangout:

Safe Harbor Act:
This release includes forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward looking statements in order to reflect events or circumstances that may arise after the date of this release.


Jerry Grisaffi
Email Contact

Investor Relations:
The Eversull Group, Inc.
Jack Eversull
Email Contact

0 198

PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials

NEW YORK, NY–(Marketwired – April 23, 2015) -PharmaCyte Biotech (PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The international biotech firm is already set to head into Phase 2b clinical trials in advanced inoperable pancreatic cancer later this year in Australia. PharmaCyte even made headlines in the diabetes industry two weeks ago after a study was published that stated its Melligen cell line could produce insulin in diabetic mice.

This news essentially means the company is well on its way to reversing the diabetes condition if the cell line proves to be safe, and those cells can be encapsulated using PharmaCyte Biotech’s signature live-cell encapsulation technology, Cell in a Box®.

While this research could potentially serve as blockbuster news for the future of PharmaCyte Biotech’s diabetes treatment, it is another study that has the company’s investors a little preoccupied these days. Those who follow the Silver Spring, Maryland, biotech are waiting on pins and needles for what should be extremely promising data from a follow-up preclinical study being conducted in the U.S. to treat the onset of malignant ascites fluid.

The results of this highly anticipated study should lead the company right to the Food and Drug Administration’s (FDA) door requesting to begin a Phase 1 human clinical trial to treat a “quality of life” symptom that all abdominal cancer patients deal with regularly. The study is being performed at the prestigious Translational Drug Development (TD2) in Scottsdale, Arizona, under the watchful eye of renowned oncologist, Dr. Daniel Von Hoff.

In the initial preclinical study, TD2 used 4 groups of mice that were implanted with human ovarian cancer cells in the peritoneal cavity to determine if PharmaCyte Biotech’s pancreatic cancer treatment, which combines Cell in a Box with the anticancer drug ifosfamide, could, in fact, have an effect on slowing the accumulation of the dangerous fluid.

At the end of that study, PharmaCyte announced that the mice receiving the company’s treatment “produced a significant survival advantage over those non-treated mice.” Another finding in the study was that the data from the mice treated with the company’s technology proved that Cell in a Box plus ifosfamide performed as well as cisplatin, which is the current standard of care for ovarian cancer.

But interestingly, what has many investors on the edge of their seats waiting to see the latest results is that when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin in the initial study, the survival rate was “greatly enhanced.” While this was an unexpected result from the study, it could potentially be great news for investors and for those patients who live with one of the many abdominal cancers like pancreatic cancer.

In the follow-up preclinical study, the company added many more groups of mice to gather as much data as possible to present the best possible scenario in slowing the onset of the malignant fluid. This time TD2 is studying 12 groups of mice with 10 mice in each group. Because this is a treatment that can potentially improve the “quality of life” in cancer patients, it is anticipated that results equal to or better than the first preclinical study will back up the earlier data and just might mean that PharmaCyte has a great opportunity to set its attention on becoming the standard of care for malignant ascites.

As investors eagerly wait for those results from PharmaCyte, it is the company that could be eagerly waiting on the data as well to find out what new bit of data they could uncover with the additional groups of mice. One thing is for sure these 120 mice have a fan club hoping the data they produce is enough to deliver right to the FDA.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.

Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at:, where you can also find all of PMCB’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.

For more information:

Stock Market Media Group

0 2288
Marijuana Stocks to Buy

This week has seen some wild swings up and down for a bunch of familiar marijuana stocks and some that may not be so familiar. It’s been a week of accumulation for some, resurrection for others and a coming out party for one. All and all investors finding the right stocks to court seem to be content with their choices for now. Lets take a snapshot of the sector in : The Week in Review….

OXIS International, Inc.(OTCMKTS:OXIS)

This week Oxis has essentially been going sideways with some nice dips and bounces of the 50 day moving average. The volume has been very good and actually getting stronger which is important for traders and investors. The swings have been between 20-30%, but what is very telling about OXIS right now is that it is mirroring the movement it had from January to February while it was in the 2 cent range for almost 2 months before it made it’s move into the 4’s & 5’s. Biotech stocks are very much in demand these days on the big boards and the OTC, LBIO which we see as Oxis’ cousin is trading at around $12 on the Nasdaq, if you held that Tony Cataldo stock when it was .02, reversed (in Order to bring in serious funding) and then up-listed then you are a seriously happy camper. So far MGMT has kept their word while increasing shareholder value. Full Disclosure Oxis is my biggest position, and i’m comfortable holding a core and trading a core on spikes. I anticipate some new news to take this to the next level. The week has been a good one with the buy/sell ratio near 70/30% in favor of buying. As for todays news about the trading resuming on the EuroNext its best summed up like this… MM’s will not be able to mess with the share price by shorting it in the OTC & Covering on the EuroNext. As I’m writing this OXIS has dipped and I just added.

MassRoots Inc (OTCMKTS:MSRT)

Thursday Mass Roots which is a very popular App in the Cannabis space went public in my eyes pretty quietly. It is a company aimed at bringing all things cannabis into a social network setting. I saw one tweet describing it as “Facebook on weed,” well at $1.07 it sounds like a bargain if they can capture 1% of FB’s audience. IPO’s are always tricky especially when it comes to technology that’s not Apple or Google. Take KING or ZNGA for example, they have gaming apps that essentially print $ every single day, yet the market does not like them. KING’s IPO last year opened at $22 and it now trades just under $17, but has gone as low as $10, ZNGA fared far worse (but they don’t have Candy Crush). MSRT should be interesting, other MMJ IPO’s in the last year include TWEED & Bedrocan all down off their IPO price, but I will reach out to the CEO next week to see what’s truly up with Mass Roots.



Has been in the last week wildly volatile, and while we like it we were able to stay objective on April 1st when we called the top and told people “taking profit will be the smartest thing you do today on $THCZ.” SInce then it has plunged from .30 to .07, bounced back to .19+ and dipped back down to .15. The last week has been a traders dream where people are making money flipping it or even gambling with their profits. THCZ’s biggest issue is that they still have a Skull & Crossbones on This symbol is obviously meant to scare people off or at the very least tell investors that there is a heightened level of risk associated with the stock. As far as the week goes all you have to do is look at the chart, its a proverbial roller coaster.


What a week it has been for PZOO as the low of the week was .0049 and as of right now the price is .01 and hit .011 yesterday when healthy profit taking took place to cool down the RSI and create a dip to .008 that was bought back by the same people holding a core and trading spikes. This Hold a core trade a core strategy is essential to PPS growth as it creates steady layers of new investors coming in. I always advise people to sell a portion of their holdings on these 30% spikes. Obviously you can ride it out, but this is a way to protect your sanity in the OTC as well as your investment. So what has changed with PZOO? Well they are partnering with a prolific lab known as Steep Hill, who is very well known in the Cannabis space and they work with many well known cannabis providers as well as have clients that generate very healthy revenues. As for PZOO, we would like to welcome them to officially in an effort to create organic awareness for the company & transparency for investors.

Blue Line Protection Group Inc (OTCBB:BLPG)

Blue Line Protection group is still what we consider here at an under the radar gem in the cannabis sector. Investors should note that they are far from just a Marijuana Security firm and offer some of the most recognized marijuana producers in the nation a cornucopia of services from banking options to vault storage of cannabis and vast sums of cash. Media wise they have been covered by CNN, CNBC, MSNBC, Fox Business and so on. Our feeling is that once people see that they are revenue producing juggernauts with a massive expansion footprint happening now the PPS will reflect their actual value. As such it is our belief that BLPG is still undervalued! With that being said the stock is trading nicely from an accumulation standpoint and is still 20% above where we started covering it (.165).

In Closing:

As for the Marijuana Sector in general there have been some companies that have come onto the radars of marijuana investors and provided great trades that we have noticed. These are companies OSLH (OSL Holdings Inc), LIBE (Liberated Energy), & PMCB (Pharmacyte Biotech). OSLH is interesting as they are up about 500% since announcing that they are potentially partnering with Cheryl Shuman one of the most visible females in the entire cannabis space. As we are now in April it’s important for traders to follow the volume, keep their ear to the ground and be on the look out sector catalysts like this one we found about the DEA tripling production of Medical Marijuana and what it can mean to MMJ being a schedule 1 drug. All in all it has been a good week for those people that have a strategy for all the Marijuana Stocks they choose to buy and sell. Cheers-

0 458

Note to Republicans: Want the Millennial Vote? Support Weed

Cannabis may in fact sway the 2016 Presidential election. In a recent segment of commentary for Roll Call, political consultant Steven Moore attracts eyes to an interesting phenomenon, which displays the millennial generation is more likely to cast a ballot in an election if the concern of cannabis is at risk. He goes on to say that if a Republican expects to get their hands on the keys to the White House in 2016, it will be important to get the nation’s youth on their team, and the best plan for succeeding with this goal may be to take a pro-cannabis platform.

However the constitutional amendment to legalize medicinal cannabis in Florida failed in last November’s election, Moore gives details that Republicans should keep a close eye to the youthful enthusiasm built up by the issue. While voter turnout across the U.S. was low, Florida experienced a 10%  gain from 2010. Also, millennia’s took over a larger share of the electorate by 6%, while seniors fell off by 10 points.

To prove even more that cannabis is a popular conern among millennial voters, look to the passing of Colorado’s Amendment 64 in 2012. During the election, the state witnessed  11% more voters under the age of 29 than in 2008. And in Washington state, there was a 4% gain in voters under the age of 30.

If medicinal cannabis makes it to the Florida ballot in 2016, which is expected, Moore proposes it will raise “marijuana law reform from a state issue to a national issue” since “most strategists see few options for a Republican in the White House if Democrats win Florida.”

Obama won Florida in 2008 with 61% of the millennial vote; 66% in 2012. However, Republicans McCain and Romney were defeated in the election by a few points. “With the margin so slim, and the trend over time going the wrong way, Republicans don’t necessarily need to win millennials, they just need to not lose them so badly,” stated by Moore.

Yet it might prove challenging for Republicans to gain the attention of millennials while protecting their base, Moore believes the problem might not be as hard to conquer as it has been in the past. “An October ’14 Gallup poll shows that nationally, one in three conservatives and four in ten Republicans favor making marijuana completely legal,” he stated, adding that “Republican support for marijuana legalization has nearly doubled since 2006.”

It is true that cannabis legalization is widely viewed as a state issue, which Moore argues would be precise if it were not “for the disproportionate influence the state of Florida has on presidential elections.”

It is for this reason that Moore throws caution to the wind with Republicans not to speak ill of cannabis reform. “Prohibitionist rhetoric may drive away the unique intersection of millennial and Republican voters likely to decide next year’s razor-thin presidential margins in Florida. Alternatively, addressing the issue in a thoughtful and strategic manner may serve to bring these voters into the GOP tent, and help assure a Republican in the White House.”

0 761

Chaos D.C.: Marijuana Becomes Legal Next Week Without Regulations

The District of Columbia’s recently passed voter Initiative 71, which legalized the growing, possession and use of cannabis in Washington DC, has nearly survived its one month congressional review and the recent law is set to take action within next week. Shortly, people 21 and older will be able to have up to two ounces of pot in there possession, cultivate six plants in their backyard, and give pot away to friends without risking the consequence of a law enforcement raid. Though, an article published Monday in The Washington Post stated “chaos” could burst in the beginning of legalizing marijuana because the federal government has halted the D.C. Council from experimenting with a regulatory system to structure the market from coming unhinged.

The issue, at least understood in the minds of some District lawmakers, is that while marijuana has reached legal stature in the backyard of the White House, there is sure  to be an rise in borderline black market dealings because the law does not come linked with regulations to accommodate consumers in the legal investment of marijuana. “Where can it be bought? Sold? Eaten? Smoked? We’re not going to have answers to any of that, and that makes me very concerned,” D.C. Council member David Grosso stated to the Post. “And as the consequences play out in the nation’s capital, he said, it could set back the entire movement: “Let’s be responsible about how we do this so we don’t have a negative image coming out.”

Unlike Colorado, marijuana users in the D.C. will not have the advantage of buying pot at a local marijuana shop. However, reports reveal that plans have already begun for marijuana clubs, which will give members with recreational cannabis for a yearly fee, although there are rumors that catered marijuana cuisine, paid for through donations, shall be provided throughout the city. Tiffany Bowden with Comfy-Tree, one of the organizers of a Marijuana Expo set to get initiated later this month on Capitol Hill, stated these types of businesses are only the starting point for the cannabis market in Washington D.C. “The District will be unique because you can’t technically sell cannabis directly,” she stated. “All that means is the traditional dispensary model as we know it will not happen. But that doesn’t mean the cannabis industry is going to be asleep. It’s actually going to be thriving in Washington.”

This off beat direction from the traditional model, like the system developed in Colorado, is what some assume will lead to Chaos inour nations capital – all due to Congress’ eagerness to interfere with the District’s cannabis laws. The concern is that industrious minds have read between the lines of the initiative and are getting ready to get a portion of the clearly  non-existent market share when the law comes to pass on February 26. According to the Post, D.C. Attorney General Karl Racine is showing law enforcement how to go about  the new law, but there are still so many unanswered questions, especially in connection to marijuana consumption and the definition of “remuneration.” In fact, during a recent sit down with Mayor Muriel Bowser, Council member Grosso asked her what would happen to a person if apprehended from using pot outside of a “cannabis club,” and she was unable to give clear answer.

Interestingly, Initiative 71 was picked up to influence growing marijuana from home, and was in no way intended to be a stepping-stone to a retail marijuana market. However, while the capitals lawmakers are hurting in their attempts to establish a taxed and regulated cannabis market for at least the next year, it looks like entrepreneurs are gearing up to push the envelope of the law in order to capitalize on marijuana once it is officially legal… but will this prove toe chaos? Obstacles, possibly, but surely nothing beyond a reasonable answer.

0 983

4 ways cannabis is good for your brain — and may save your life

Current investigations are showing that marijuana extracts help to protect and benefit the human brain. Here are some ways scientists are revealing that marijuana actually helps to keep your brain safe from sickness, dementia and in some cases death

#4 – Cannabis promotes new brain cell growth

Government scare campaigns more times then not claim that cannabis kills brain cells, but now we are discovering the truth. Those studies in the ’70s were not given credit, by the use of strapping a gas mask on the mouth of a monkey and delivering hundreds of joints worth of marijuana smoke. The monkeys experienced lack of oxygen, and that was the cause of why their brain cells died.

Modern investigations are now showing the opposite. The main compounds in cannabis spur the development of new brain cells! Back in 2005, Dr. Xia Zhang at the University of Saskatchewan presented that cannabinoids cause “neurogenesis” – which is defined as they aid new braincell growth

“Most ‘drugs of abuse’ suppress neurogenesis,” stated Dr. Zhang. “Only marijuana promotes neurogenesis.”

Scientists in Brazil found more on this research, showing examples, in 2013 that CBD, another compound in cannabis, also causes new braincells to grow, Researchers in Italy then had the same conclusion with CBC, another “cannabinoid” found in marijuana resin.

Now there is no question that cannabinoids cause new brain cells to sprout up in the hippocampus. This helps explain prior investigations displaying that cannabinoids effectively help mood disorders such as depression, anxiety and stress – they are all in connection to a lack of adult neurogenesis.

#3 – Cannabis prevents Alzheimer’s

Close to 5 millions Americans are diagnosed  with Alzheimer’s. There could be light at the end of the tunnel. Modern analysis reveals that utilizing marijuana helps prevent the cause of Alzheimer’s and dementia by cleaning away beta-amyloid “brain plaque.” A  study conducted about cannabis and Alzheimer’s was headed by Dr. Chuanhai Cao, PhD, a neuroscientist at the Byrd Alzheimer’s Institute. “THC is known to be a potent antioxidant with neuroprotective properties,” said Cao, explaining that THC “directly affects Alzheimer’s pathology by decreasing amyloid beta levels, inhibiting its aggregation, and enhancing mitochondrial function.”

This proved earlier research, for example research from 2008 which discovered that THC “simultaneously treated both the symptoms and progression of Alzheimer’s disease.” This study relate was, “compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is considerably superior.”

These investigations used very low levels of THC to find these answers – the levels you might find in a marijuana user that doesn’t smoke often. So where are the headlines displaying “Smoking Cannabis Prevents Alzheimer’s”?

#2 – Cannabis prevents brain damage after strokes and trauma

Multiple recent investigations have discovered that cannabinoids defend the brain from permanent damage after severe medical conditions. Research found in 2012 and 2013 showed that a low dose of THC give protection to mice’s brains from suffering by carbon monoxide and head injuries. Researchers show that THC “protected brain cells and preserved cognitive function over time” and influenced the idea that it could be used preventively, for ongoing defense.

Research in 2014 found that people with low amounts of THC in their body were near 80% less likely to die from major head trauma than those without. This last study is really quite phenomenal and should have been headline in the news. Scientist analyzed blood samples from hundreds of people who had suffered head trauma, and discovered that people with small amounts of cannabinoids in their system were 80% less likely to be killed from head injuries.

This means that in a group of occasional marijuana users and a group of abstainers who have similar brain injuries, the marijuana users will have only 2 deaths for every 10 suffered by the whodo not use marijuana. There are 52,000 fatalities every year from traumatic head injury in America. This investigation showed that if every adult American had a pull of marijuana once a week, 20% of those deaths would not occur  – that’s close to 41,600 people that could be saved, every year.  Still this hasn’t made front page news?

#1 – Cannabis extracts treat brain cancer

One interesting use of cannabinoids is in the aid of cancer treatment. Repeated laboratory and animal research have discovered that cannabinoids eliminate cancer cells and shrink the size of tumors, while aiding to defend normal cells. New information involves a 2012 study displaying that CBD blocked metastasis in aggressive forms of cancer,  a 2013 investigation showing that a mix of six cannabinoids eliminated leukemia cell, and a 2014 study revealing that THC and CBD could be mixed with traditional chemotherapy to produce “dramatic reductions” in brain tumour size.

Using marijuana extracts for brain cancer is nothing that hasn’t been known to the medical world. Research in 1998, found that THC “induces apoptosis [cell death] in C6 glioma cells” – an aggressive type of brain cancer. A 2009 study dave details stating that THC acted “to kill cancer cells, while it does not affect normal cells” in the brain. The medical advantages of cannabis and cannabinoids are infinite, and we are in a day and age where everyone is allowed full access to this wonderful healing plant. You never know? One day maybe we will even get to use outdoor-grown cannabis to develop vast quantities of pure, cost efficient cannabinoids for the millions of people across the nation who need them.

0 641

Medbox’s Largest Shareholder Comments on Recent Events and the Company’s Outlook for 2015

LOS ANGELES, CA–(Marketwired – Dec 30, 2014) – P. Vincent Mehdizadeh — Founder and Majority Shareholder of Medbox, Inc. (OTCQB: MDBX) issued a letter to fellow shareholders today regarding his vision for the future of the company and insight into recent developments affecting the company.

The letter stated:

“Dear Medbox Shareholders:

It has truly been an interesting journey during the last 2 years. When I commenced operations of the private company in 2010 that later became Medbox, I never anticipated that the company would be as noteworthy and relevant as we are today. The company has a rare blend of consulting and patented technology that gives entrepreneurs a jumpstart on realizing their dreams of operating a business in a newly emerging industry. I have thoroughly enjoyed watching our client’s dreams be realized, along with our shareholders that have watched our company grow and prosper over these years.

Medbox rocketed to stardom and notoriety amidst a positive outlook for the marijuana industry in November of 2012 based on favorable election results and highlighted by several media sources, including the Wall Street Journal, which ushered in what many have called the ‘Green Rush.’ In the days that followed, the company’s stock price saw unprecedented increases that was said to have resulted from investors looking to participate in ‘The Next Great American Industry.’ Up until 3 months ago, I was involved in almost every decision the company made, and my decision at that time was to caution investors about investing in any company in the marijuana industry because of the inherent risks. We also publicly cautioned investors to temper their expectations about our stock and to make informed investment decisions. The company fielded criticism in doing so, but we felt that separating ourselves from other public company industry participants in our sector and focusing on protecting investors as best we could was a beneficial direction for the company. In my opinion, one of the keys to Medbox’s success has been superior corporate messaging and timely dissemination of information to our shareholders.

Since that point in time a little over two years ago, I have made it my mission to take the company from being a non-reporting pinksheet to being a fully reporting SEC Filer. I took it upon myself to set these goals and achieve them for the benefit of the company and its shareholders. We did this to have an increased level of transparency so that investors can think of Medbox as the public company standard for respectability and reliability in the newly emerging marijuana industry that was taking shape. As a result, we engaged a Public Company Accounting and Oversight Board (PCAOB) registered auditor, Q Accountancy Corporation, and also hired a full-time Chief Financial Officer, Thomas Iwanski, a CPA with excellent references and extensive public company experience.

Since the company engaged Mr. Iwanski and Q Accountancy Corporation, I also recruited a star-studded board and together we appointed Guy Marsala to lead the company as the Chief Executive Officer. As it was explained to me, in situations where a new CEO is brought on, they typically look to appoint their own Chief Financial Officer. Thus, when Mr. Marsala decided to replace Mr. Iwanski as CFO, I did not give it a second thought, although I was sad to see him go since his experience with public company oversight was superb.

Today, the company’s current management issued a statement regarding the company’s financials. Prior management, including Mr. Iwanski and the company’s current auditor, both disagree with current management’s position on the matter. Both the current auditor and prior CFO have made their opinions known to current management, to no avail. Both have stated that they had support for recognizing revenue in the periods in which they were recognized. However, the company’s current CFO has a difference of opinion on that aspect and believes that the revenue in question should be recognized in later periods, which has now resulted in a proposed restatement set to occur. This fact along with the fact that the revenue items in dispute amount to less than 10% of the total revenue booked for 2013, was not accurately discussed in the disclosure released this morning. 

As stated previously in this letter, corporate messaging and communication to shareholders is one of the many aspects that made Medbox a great company. I now feel the company is not doing enough to accurately disclose matters in a manner that is easy to understand and digest by the public. Stating that the current CFO has a difference of opinion with the prior CFO and current auditor would have gone a long way to explaining the situation properly. Instead, we have the inaccurate and incomplete disclosure that was released today that leaves the public with more questions than giving them the answers they need to understand the situation.

As we were on a path to transition to NASDAQ and had filed an application to be listed on that exchange, I felt that since I had a checkered past that was disclosed in company filings it would tarnish the Medbox brand if I stayed involved in any capacity other than as a consultant to the company. Although these offenses were non-violent, non-securities related offenses, all of which resulted in probation and all occurring prior to Medbox, I still felt that the company would always be a target of ‘short and distort’ campaigns by financial bloggers if I remained an Officer or Director. To that end, I recently gave full control to the board and current management to steer the ship and navigate the company properly. Recent events have caused me to call into question whether current management and the board of directors has enough industry experience to properly run this company. It is for this reason that I will be adding industry-experienced members to the board to work with the current board members to more effectively operate the company. I will also be taking a more active role with the company again to ensure our short-term and long-term goals can be achieved.

I believe that a founder’s passion separates a typical company from a company that achieves the utmost success. The company needs my help now more than ever, and I intend to fill that need to the best of my ability going forward. I look forward to a strong and prosperous future for Medbox.


P. Vincent Mehdizadeh”

About P. Vincent Mehdizadeh, Founder and Majority Shareholder at Medbox, Inc.
P. Vincent Mehdizadeh founded Medbox’s main subsidiary, Medicine Dispensing Systems, in February 2008. He commenced operations for that company in 2010, and in December of 2011 sold that company to what became Medbox, Inc. Mr. Mehdizadeh served as senior consultant from December 2012 until May 10, 2013 for Medbox, Inc. and then transitioned to Chief Operations Officer and Board Chairman for Medbox, Inc. through May of 2014. Mr. Mehdizadeh was responsible for creating the 2 main patents behind the company’s technology, helping to assemble the talented management team at Medbox, and also developing the concept behind the business models driving revenue for the company.

About Medbox, Inc:
Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Headquartered in Los Angeles, Medbox, through its wholly owned subsidiary, Medicine Dispensing Systems, offers their patented systems, software and consulting services to pharmacies, alternative medicine dispensaries and local governments in the U.S. In addition, through its wholly owned subsidiary, Vaporfection International, Inc. (, the company offers an industry award winning medical vaporizer product. Medbox, through its newly established subsidiaries, is in development of the following ancillary services catered to the alternative medicine industry: merchant services and armored transport for cash deposits, cannabidiol research and development, real estate acquisitions and subsequent lease programs to alternative medicine dispensaries, and alternative medicine dispensary management services.

Media Inquiries:
The Innovation Agency
Email Contact

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact